Latest news with #AnupamRama
Business Insider
9 hours ago
- Business
- Business Insider
Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
9 hours ago
- Business
- Business Insider
J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)
In a report released on June 20, Anupam Rama from J.P. Morgan maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $8.50. The company's shares closed last Friday at $9.30. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Rama has an average return of -6.9% and a 37.70% success rate on recommended stocks. SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $9.04, which is a -2.80% downside from current levels. In a report released on June 20, Robert W. Baird also maintained a Hold rating on the stock with a $9.00 price target. The company has a one-year high of $13.47 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.52M.
Yahoo
05-03-2025
- Business
- Yahoo
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million. JP Morgan maintains the Overweight rating with a price forecast of $54. Analyst Anupam Rama says Apellis' lead asset, pegcetacoplan (Syfovre/Empaveli), represents a differentiated asset in the complement space, with opportunities across ophthalmology, hematology, neurology, and nephrology indications. Also Read: The company generated Syfovre sales of $167.8 million and $611.9 million for the fourth quarter and full year 2024, respectively. Delivered approximately 94,000 Syfovre doses to physician practices in the fourth quarter, including approximately 89,000 commercial vials and 4,600 samples. More than 510,000 Syfovre injections, including clinical trials, are estimated to have been administered since launch through December 2024. JP Morgan views Syfovre as an over $1.5 billion peak potential drug, even with conservative assumptions. 'Overall, physicians continue to use the product, driving growth, and we anticipate a fundamental and sentiment shift driving upside in APLS shares,' the analyst writes. Analyst Rama also expects that the Empaveli C3 glomerulopathy and primary immune complex glomerulonephritis (C3G/IC-MPGN) opportunity will be a driver for Apellis stock. The company has submitted a supplemental marketing application for approval of Empaveli based on Phase 3 VALIANT results at six months; if approved, a U.S. launch is expected in 2H 2025. Price Action: APLS stock is up 3.27% at $25.87 at the last check Wednesday. Read Next:Date Firm Action From To Mar 2022 Goldman Sachs Maintains Buy Mar 2022 Raymond James Maintains Strong Buy Jan 2022 Raymond James Maintains Strong Buy View More Analyst Ratings for APLS View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APELLIS PHARMACEUTICALS (APLS): Free Stock Analysis Report This article Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
